Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Osterlind, K.
Right arrow Articles by Andersen, P. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Osterlind, K.
Right arrow Articles by Andersen, P. K.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Journal of Clinical Oncology, Vol 4, 1307-1313, Copyright © 1986 by American Society of Clinical Oncology


ARTICLES

Long-term disease-free survival in small-cell carcinoma of the lung: a study of clinical determinants

K Osterlind, HH Hansen, M Hansen, P Dombernowsky and PK Andersen

The influence of treatment and of pretreatment patient characteristics on the probability of long-term disease-free survival in small-cell lung cancer (SCLC) was investigated in a consecutive series of 874 patients. The patients were included in six controlled treatment trials from 1973 to 1981, using different combinations of chemotherapy with or without irradiation. All patients underwent pretreatment staging, including bronchoscopy, peritoneoscopy with liver biopsy, and bone marrow examination. The same procedures were repeated in patients without overt signs of disease 18 months from initiation of treatment, and patients without evidence of SCLC were regarded as long-term survivors. Seventy-two patients were disease-free at restaging, corresponding to 13% of 443 patients with limited-stage disease and 3% of 431 patients with extensive-stage disease. The possible relationship between different pretreatment variables and the probability of 18 months' disease-free survival was investigated by multiple regression analysis. Disease extent was the most important determinant of long- term survival. Being a woman was a positive factor and hypouricemia had negative influence on the long-term results, while features such as performance status and serum lactate dehydrogenase (LDH) did not have significant influence in the regression model. Differences between the efficacy of the applied treatment regimens were less in limited disease than they were in extensive disease, in which six-agent regimens of alternating chemotherapy was significantly better than treatment with three- or four-agent regimens. Accordingly, disease extent seems to be the most pivotal determinant of long-term survival in SCLC, but influence of the patient's sex and serum urate concentration should also be considered.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Ann OncolHome page
P. Wheatley-Price, C. Ma, L. F. Ashcroft, M. Nankivell, R. J. Stephens, S. C. White, P. Lorigan, N. Thatcher, F. H. Blackhall, and F. A. Shepherd
The strength of female sex as a prognostic factor in small-cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit
Ann. Onc., February 1, 2010; 21(2): 232 - 237.
[Abstract] [Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
T. Sher, G. K. Dy, and A. A. Adjei
Small Cell Lung Cancer
Mayo Clin. Proc., March 1, 2008; 83(3): 355 - 367.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
B. E. Lally, J. J. Urbanic, A. W. Blackstock, A. A. Miller, and M. C. Perry
Small Cell Lung Cancer: Have We Made Any Progress Over the Last 25 Years?
Oncologist, September 1, 2007; 12(9): 1096 - 1104.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. Singh, W. Parulekar, N. Murray, R. Feld, W. K. Evans, D. Tu, and F. A. Shepherd
Influence of Sex on Toxicity and Treatment Outcome in Small-Cell Lung Cancer
J. Clin. Oncol., February 1, 2005; 23(4): 850 - 856.
[Abstract] [Full Text] [PDF]


Home page
RadioGraphicsHome page
R. Komaki, M. H. Chasen, W. D. Travis, J. B. Putnam, F. V. Fossella, R. W. Byhardt, and J. Y. Ro
Oncodiagnosis Panel: 1999: Cancer of the Lung: Oncodiagnosis
RadioGraphics, November 1, 2001; 21(6): 1573 - 1596.
[Full Text] [PDF]


Home page
ChestHome page
A. Elias
Hematopoietic Stem Cell Transplantation for Small Cell Lung Cancer*
Chest, December 1, 1999; 116 (2009): 531S - 538S.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. Elias, J. Ibrahim, A. T. Skarin, C. Wheeler, M. McCauley, L. Ayash, P. Richardson, L. Schnipper, K. H. Antman, and E. Frei III
Dose-Intensive Therapy for Limited-Stage Small-Cell Lung Cancer: Long-Term Outcome
J. Clin. Oncol., April 1, 1999; 17(4): 1175 - 1175.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
F. R. HIRSCH, K. OSTERLIND, P. E. G. KRISTJANSEN, and H. H. HANSEN
Bone Marrow Examination in Small Cell Lung Cancer
Ann Intern Med, June 1, 1987; 106(6): 913 - 913.
[Abstract] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 1986 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online